Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Ceska Trebova

2 clinical trials in Ceska Trebova, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ceska Trebova at a glance
2
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Ceska Trebova

Open in trial search

Cardiac failure+1

Recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not yet recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Other cities in Czechia

The busiest research cities in the country

All 158 cities in Czechia

Clinical research in Ceska Trebova

What the registry says about research in the country

01 Ceska Trebova
Cardiovascular Diseases
Clinical trial activity in Ceska Trebova is focused entirely on cardiovascular diseases, with studies aimed at reducing serious heart and vascular events and improving outcomes for people at elevated risk. The research landscape is centered on prevention, risk reduction, and better long-term management of major cardiovascular disease. Study of atherosclerotic cardiovascular disease and related complications Research in broader cardiovascular disease prevention Trials for HFpEF or HFmrEF with obesity These trials are evaluating new treatment approaches against placebo to see whether they can lower the risk of events such as heart attack, stroke, urgent revascularization, or heart failure-related hospital visits.
Heart and Vascular Event Prevention
A key area of research is the prevention of major cardiovascular events in people at high risk. The studies are designed to test whether new therapies can better protect patients from life-threatening outcomes involving the heart, brain, and blood vessels. Reducing risk of myocardial infarction Preventing ischaemic stroke and other vascular complications Lowering the chance of urgent arterial procedures This line of research reflects a strong focus on improving the effectiveness of preventive care for people who may be vulnerable to first or recurrent serious events.
Lipoprotein(a) and Atherosclerosis Research
One trial is exploring whether targeting lipoprotein(a) can reduce the chance of first major coronary events in people with elevated levels and no prior event. The goal is to improve prevention strategies for atherosclerotic cardiovascular disease. Focus on elevated Lp(a) Assessment of risk for coronary heart disease Testing a new approach to first-event prevention This research highlights the growing interest in biomarkers that may help identify and treat cardiovascular risk more precisely.
Heart Failure and Obesity
Another area of interest is heart failure in people living with obesity, especially those with HFpEF or HFmrEF. The study is evaluating whether a new therapy can improve outcomes when added to standard care. HFpEF and HFmrEF populations Obesity as an important linked condition Measuring reduction in heart failure-related events The research is aimed at helping patients who face overlapping metabolic and cardiac challenges, with the broader goal of improving day-to-day stability and reducing urgent care needs.
Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.